Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooled post hoc analysis.
Legendre, Christophe M; Campistol, Josep M; Feldkamp, Thorsten; Remuzzi, Giuseppe; Kincaid, John F; Lommelé, Åsa; Wang, Jimmy; Weekers, Laurent E; Sheerin, Neil S.
; 30(12): 1275-1283, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28801959
Favorable long-term outcomes of isolated liver transplantation in a child with atypical hemolytic uremic syndrome caused by a novel complement factor H mutationâ©.
Prophylactic eculizumab for kidney transplantation in a child with atypical hemolytic uremic syndrome due to complement factor H mutation.
Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.
Long-term successful liver-kidney transplantation in a child with atypical hemolytic uremic syndrome caused by homozygous factor H deficiency.
Favorable four-yr outcome after renal transplantation in a patient with complement factor H antibody and CFHR1/CFHR3 gene mutation-associated HUS.
Absence of thrombocytopaenia and/or microangiopathic haemolytic anaemia does not reliably exclude recurrence of atypical haemolytic uraemic syndrome after kidney transplantation.
Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.
Successful living-related renal transplantation in a patient with factor H antibody-associated atypical hemolytic uremic syndrome.
Genetica della Sindrome Emolitico Uremica atipica e recidiva nel trapianto.
Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome.